WO2024095053A1 - Novel non-oral formulations of factor xa inhibitors and process for preparation thereof - Google Patents
Novel non-oral formulations of factor xa inhibitors and process for preparation thereof Download PDFInfo
- Publication number
- WO2024095053A1 WO2024095053A1 PCT/IB2022/062795 IB2022062795W WO2024095053A1 WO 2024095053 A1 WO2024095053 A1 WO 2024095053A1 IB 2022062795 W IB2022062795 W IB 2022062795W WO 2024095053 A1 WO2024095053 A1 WO 2024095053A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- factor
- formulation
- inhibitor
- inhibitors
- surface active
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 122
- 238000009472 formulation Methods 0.000 title claims abstract description 98
- 229940123583 Factor Xa inhibitor Drugs 0.000 title claims abstract description 72
- 238000000034 method Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 5
- 239000003981 vehicle Substances 0.000 claims abstract description 33
- 239000002904 solvent Substances 0.000 claims abstract description 27
- 239000004094 surface-active agent Substances 0.000 claims abstract description 25
- 239000003381 stabilizer Substances 0.000 claims abstract description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 54
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 229960003886 apixaban Drugs 0.000 claims description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 claims description 24
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 claims description 24
- 229960000622 edoxaban Drugs 0.000 claims description 24
- 229950010535 razaxaban Drugs 0.000 claims description 24
- 229960001148 rivaroxaban Drugs 0.000 claims description 24
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims description 24
- 229950011103 betrixaban Drugs 0.000 claims description 22
- XHOLNRLADUSQLD-UHFFFAOYSA-N betrixaban Chemical compound C=1C=C(Cl)C=NC=1NC(=O)C1=CC(OC)=CC=C1NC(=O)C1=CC=C(C(=N)N(C)C)C=C1 XHOLNRLADUSQLD-UHFFFAOYSA-N 0.000 claims description 22
- 239000002202 Polyethylene glycol Substances 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 235000019441 ethanol Nutrition 0.000 claims description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 16
- 235000011187 glycerol Nutrition 0.000 claims description 13
- -1 fatty acid esters Chemical class 0.000 claims description 12
- 235000013772 propylene glycol Nutrition 0.000 claims description 9
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 8
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 8
- 229920001400 block copolymer Polymers 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 229920001983 poloxamer Polymers 0.000 claims description 8
- 229920000136 polysorbate Polymers 0.000 claims description 8
- 229940068965 polysorbates Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229940072106 hydroxystearate Drugs 0.000 claims description 2
- 150000004668 long chain fatty acids Chemical class 0.000 claims description 2
- 229960003511 macrogol Drugs 0.000 claims description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 29
- 230000000699 topical effect Effects 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 3
- 238000012371 Aseptic Filling Methods 0.000 description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000011540 hip replacement Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000013150 knee replacement Methods 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- the present invention relates to a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers.
- the present invention also relates to a process for preparing novel formulation of factor Xa inhibitor for non-oral route of administration.
- the present invention also relates to a novel non-oral formulation of factor Xa inhibitors for parenteral, topical, nasal, transdermal and ophthalmic administration.
- Factor Xa inhibitors are small molecules that selectively and reversibly bind to the active site of activated factor X (Xa), which blocks the interaction with its substrate in a rapid and competitive fashion, therefore inhibiting the final effects of thrombin generation.
- factor Xa inhibitors such as Apixaban, Razaxaban, Betrixaban Rivaroxaban, and Edoxaban.
- Apixaban is a known compound having the below structure and molecular weight 459.50 g/mol.
- Razaxaban is a known compound having the below structure and molecular weight 528.5 g/mol.
- Edoxaban is a known compound having the below structure and molecular weight 548.1 g/mol.
- Rivaroxaban is a known compound having the below structure and molecular weight 435.9 g/mol.
- Betrixaban is a known compound having the below structure and molecular weight 451.9 g/mol.
- U.S. patent application 2015/0224053 Al teaches a oral liquid formulation comprising Apixaban and a vehicle, the vehicle comprising water and at least two solubilizers selected from the group consisting of a non-ionic surfactant, an ionic surfactant, a hydrophilic polymer, ethanol, a polyhydric alcohol, a polyethylene glycol, and a carbohydrate, wherein a solubility of Apixaban in the vehicle is at least 0.50 mg/mL.
- PCT application WO 2007/022165 A2 teaches a pharmaceutical formulation comprising a factor Xa inhibitor and a substituted-0-cyclodextrin as solubilizing agent wherein the formulation is in the form of an injectable formulation.
- Non-oral formulation of factor Xa inhibitor such as Apixaban or Razaxaban or Edoxaban or Rivaroxaban or Betrixaban eases the administration in subconscious, non-cooperative or pediatric or geriatric patients who have difficulty in swallowing a dosage form through oral route.
- Factor Xa inhibitors such as Apixaban or Razaxaban are weak base.
- Apixaban has pH dependent instability and its free base form has extremely low aqueous solubility which is less than 0.04 mg/mL.
- Edoxaban and Rivaroxaban also have low aqueous solubility, 0.14 mg/mL and 0.025 mg/mL, respectively.
- Anticipated human dose of Apixaban or Razaxaban or Edoxaban or Rivaroxaban or Betrixaban is about 2.5 to 15 mg.
- a solution of high drug concentration for example 2 mg/mL. Since, the solubility of Apixaban or Razaxaban or Edoxaban or Rivaroxaban could not be increased to needed level i.e. 2 mg/mL, by adjusting pH in physiological range [pH 1.2-6.8] due to pH dependent instability.
- a novel co-solvency approach is proposed for current formulation.
- the objective of the present invention is to provide a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co- solvents and stabilizers.
- Another objective of the present invention is to provide a non-oral formulation of factor Xa inhibitors wherein factor Xa inhibitors are selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
- Another objective of the present invention is to provide a non-oral formulation of factor Xa inhibitors prepared using pharmaceutically acceptable excipients present within permitted IIG limit.
- Another objective of the present invention is to provide a process for preparing novel formulation of factor Xa inhibitor for non-oral route of administration.
- Another objective of the present invention is to provide a novel non-oral formulation of factor Xa inhibitors for parenteral, topical, nasal, transdermal and ophthalmic administration.
- the present invention provides a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers.
- One embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors with excipients within permitted IIG limit for I.V. administration, wherein factor Xa inhibitors are selected from the group of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
- factor Xa inhibitors are selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
- Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor, b) vehicles, c) surface active agents, and d) co- solvents.
- Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor, b) vehicles, c) surface active agents, d) stabilizers and e) co- solvents.
- Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor, b) 5% to 90% w/w of vehicles, c) 0.001% to 40% w/w of surface active agents and d) 10% to 90% w/w of co- solvents.
- Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor, b) 5% to 90% w/w of vehicles, c) 0.001% to 40% w/w of surface active agents, d) 10% to 90% w/w of co-solvents, and e) 1% to 30% w/w of stabilizers.
- factor Xa inhibitors comprising: a) factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) water as vehicle, c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d) co- solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof.
- factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban
- water as vehicle c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d
- factor Xa inhibitors comprising: a) factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) water as vehicle, c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), d) co- solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof and e) stabilizers selected from glycerin, propylene glycol, sorbitol, and mannitol.
- factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban
- water as vehicle c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters
- Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) 5% to 90% w/w of water as vehicle, c) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof.
- factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban
- Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) 5% to 90% w/w of water as vehicle, f) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), g) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof and c) 1% to 30% w/w of stabilizers selected from glycerin, sorbitol, and mannitol.
- surface active agents selected
- Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitors.
- Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor for parenteral, topical, nasal, transdermal and opthalmic administration.
- Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising: a) adding factor Xa inhibitor and excipients under continuous mixing using stirring, b) making the final volume with water for injection, and c) heating the mixture if required.
- Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture if required.
- Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents, stabilizers and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture if required.
- the solubility of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban in this vehicle is atleast 1.5 mg/mL.
- the present invention has better acceptability as compared to earlier claimed inventions of the same group of drugs.
- the formulation is suitable for bolus injection, intravenous infusion, topical, nasal, transdermal and ophthalmic administration.
- in another embodiment of the present invention is a method for treating the risk of stroke and systemic embolism in nonvalular atrial fibrillation patients and deep vein thrombosis and pulmonary embolism after hip or knee replacement surgery, administered to patient in need, thereof a non-oral formulation of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban are therapeutically active.
- the subject invention describes new formulations of factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban for administration which includes non-oral formulation and method for making and using the same.
- Drug solubility is minimum requirement for designing any dosage form and it is more critical when designing a formulation of poorly soluble drug like factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban. Because of low solubility associated with factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, the bioavailability is limited and hence, solubility enhancement is necessary.
- factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
- the method of making and using novel non-oral formulation of poorly soluble factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban disclosed in this invention addresses the enhancement of patient acceptability for same class of drugs.
- the factor Xa inhibitor is selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
- the factor Xa inhibitor used in formulations of present invention is in the range of about 0.001% to 10% w/w of total weight of the formulation.
- the vehicle used in the formulations of the present invention is water.
- the vehicle used in formulations of present invention is in the range of about 5% to 90% w/w of total weight of the formulation.
- the surface active agents used in the present invention are selected from nonionic surface active agents such as polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), polyoxyethylene castor oil derivative, polyoxyglyceride, vitamin E polyethylene glycol succinate, and macrogol 15 hydroxystearate and combinations thereof.
- nonionic surface active agents such as polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), polyoxyethylene castor oil derivative, polyoxyglyceride, vitamin E polyethylene glycol succinate, and macrogol 15 hydroxystearate and combinations thereof.
- the surface active agents used in formulations of present invention is in the range of about 0.001% to 40% w/w of total weight of the formulation.
- the co- solvents used in the present invention are selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, ester of a medium or long chain fatty acid such as a mono- di- or triglyceride, phospholipids, dimethylsulfoxide, dimethylacetamide and combinations thereof.
- the co- solvents used in formulations of present invention is in the range of about 1% to 90% w/w of total weight of the formulation.
- the stabilizers used in the present invention are selected from glycerin, sorbitol, and mannitol.
- the stabilizers used in formulations of present invention are in the range of about 1% to 90% w/w of total weight of the formulation.
- the said invention is stable as confirmed from stability studies conducted on prepared formulations.
- the product thus formulated can be used for treatment of risk of stroke, systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis and pulmonary embolism after hip or knee replacement surgery.
- the dosage must be individualized by treating clinician.
- the formulation of the present invention is manufactured by dissolving surface active agent in vehicle followed by adding one or more co-solvent’s or co-solvent and stabilizer and finally adding factor Xa inhibitor in the vehicle under continuous mixing using stirring. Final volume was made up by water for injection. Mixture was heated at 40-80°C for 10-30 minutes if required, to obtain clear solution upon cooling to room temperature.
- the solution was free from particulate matter by visual inspection and was filtered by sterilizing grade filter followed by aseptic filling into vials or ampoules or prefilled syringes. If required, the final product was sterilized by autoclaving.
- Target fill volume was 3.5 mL including 0.5 mL overfill for vial or needle or ampoule hold up.
- Example 2 The formulations of example 2 were prepared as per manufacturing process described in Example 1.
- Example 4 The formulations of example 4 were prepared as per manufacturing process described in Example 1.
- Example 5 The formulations of example 5 were prepared as per manufacturing process described in Example 1.
- EXAMPLE 6 The formulations of example 6 were prepared as per manufacturing process described in Example 1.
- Example 7 The formulations of example 7 were prepared as per manufacturing process described in Example 1.
- Example 8 The formulations of example 8 were prepared as per manufacturing process described in Example 1.
- Example 9 The formulations of example 9 were prepared as per manufacturing process described in Example 1.
- Table No. 11 Composition for formulation 11 The formulations of example 11 were prepared as per manufacturing process described in Example 1.
- Example 12 The formulations of example 12 were prepared as per manufacturing process described in Example 1.
- Example 13 The formulations of example 13 were prepared as per manufacturing process described in Example 1.
- Example 14 The formulations of example 14 were prepared as per manufacturing process described in Example 1.
- Table No. 16 Composition for formulation 16 The formulations of example 16 were prepared as per manufacturing process described in Example 1.
- Example 17 The formulations of example 17 were prepared as per manufacturing process described in Example 1.
- Example 18 The formulations of example 18 were prepared as per manufacturing process described in Example 1.
- Example 19 The formulations of example 19 were prepared as per manufacturing process described in Example 1.
- Example 20 The formulations of example 20 were prepared as per manufacturing process described in Example 1.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers. The present invention also relates to a process for preparing novel formulation of factor Xa inhibitor for non-oral route of administration. The present invention also relates to a novel non-oral formulation of factor Xa inhibitors for parenteral, topical, nasal, transdermal and ophthalmic administration.
Description
NOVEL NON-ORAL FORMULATIONS OF FACTOR Xa INHIBITORS AND PROCESS FOR PREPARATION THEREOF
FIELD OF INVENTION
The present invention relates to a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers.
The present invention also relates to a process for preparing novel formulation of factor Xa inhibitor for non-oral route of administration.
The present invention also relates to a novel non-oral formulation of factor Xa inhibitors for parenteral, topical, nasal, transdermal and ophthalmic administration.
BACKGROUND OF INVENTION
Factor Xa inhibitors are small molecules that selectively and reversibly bind to the active site of activated factor X (Xa), which blocks the interaction with its substrate in a rapid and competitive fashion, therefore inhibiting the final effects of thrombin generation.
Several factor Xa inhibitors, such as Apixaban, Razaxaban, Betrixaban Rivaroxaban, and Edoxaban.
Apixaban is a known compound having the below structure and molecular weight 459.50 g/mol.
Razaxaban is a known compound having the below structure and molecular weight 528.5 g/mol.
U.S. patent application 2015/0224053 Al teaches a oral liquid formulation comprising Apixaban and a vehicle, the vehicle comprising water and at least two solubilizers selected from the group consisting of a non-ionic surfactant, an ionic surfactant, a hydrophilic polymer, ethanol, a polyhydric alcohol, a polyethylene glycol, and a carbohydrate, wherein a solubility of Apixaban in the vehicle is at least 0.50 mg/mL.
PCT application WO 2007/022165 A2 teaches a pharmaceutical formulation comprising a factor Xa inhibitor and a substituted-0-cyclodextrin as solubilizing agent wherein the formulation is in the form of an injectable formulation.
Non-oral formulation of factor Xa inhibitor such as Apixaban or Razaxaban or Edoxaban or Rivaroxaban or Betrixaban eases the administration in subconscious, non-cooperative or pediatric or geriatric patients who have difficulty in swallowing a dosage form through oral route.
Factor Xa inhibitors such as Apixaban or Razaxaban are weak base. Reportedly, Apixaban has pH dependent instability and its free base form has extremely low aqueous solubility which is less than 0.04 mg/mL. Similarly, Edoxaban and Rivaroxaban also have low aqueous solubility, 0.14 mg/mL and 0.025 mg/mL, respectively.
Anticipated human dose of Apixaban or Razaxaban or Edoxaban or Rivaroxaban or Betrixaban is about 2.5 to 15 mg. To achieve a practical non-oral dose of less than 5 mL, a solution of high drug concentration, for example 2 mg/mL, is required.
Since, the solubility of Apixaban or Razaxaban or Edoxaban or Rivaroxaban could not be increased to needed level i.e. 2 mg/mL, by adjusting pH in physiological range [pH 1.2-6.8] due to pH dependent instability. Hence, a novel co-solvency approach is proposed for current formulation.
OBJECTIVE OF INVENTION
The objective of the present invention is to provide a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co- solvents and stabilizers.
Another objective of the present invention is to provide a non-oral formulation of factor Xa inhibitors wherein factor Xa inhibitors are selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
Another objective of the present invention is to provide a non-oral formulation of factor Xa inhibitors prepared using pharmaceutically acceptable excipients present within permitted IIG limit.
Another objective of the present invention is to provide a process for preparing novel formulation of factor Xa inhibitor for non-oral route of administration.
Another objective of the present invention is to provide a novel non-oral formulation of factor Xa inhibitors for parenteral, topical, nasal, transdermal and ophthalmic administration.
SUMMARY OF INVENTION
Accordingly, the present invention provides a novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers.
One embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors with excipients within permitted IIG limit for I.V. administration,
wherein factor Xa inhibitors are selected from the group of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
Another embodiment of the present invention provides a liquid formulation of factor Xa inhibitors, wherein factor Xa inhibitors are selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor, b) vehicles, c) surface active agents, and d) co- solvents.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor, b) vehicles, c) surface active agents, d) stabilizers and e) co- solvents.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor, b) 5% to 90% w/w of vehicles, c) 0.001% to 40% w/w of surface active agents and d) 10% to 90% w/w of co- solvents.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor, b) 5% to 90% w/w of vehicles,
c) 0.001% to 40% w/w of surface active agents, d) 10% to 90% w/w of co-solvents, and e) 1% to 30% w/w of stabilizers.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) water as vehicle, c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d) co- solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) water as vehicle, c) surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), d) co- solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof and e) stabilizers selected from glycerin, propylene glycol, sorbitol, and mannitol.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising:
a) 0.001% to 10% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) 5% to 90% w/w of water as vehicle, c) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof.
Another embodiment of the present invention provides a non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 10% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) 5% to 90% w/w of water as vehicle, f) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), g) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof and c) 1% to 30% w/w of stabilizers selected from glycerin, sorbitol, and mannitol.
Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitors.
Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor for parenteral, topical, nasal, transdermal and opthalmic administration.
Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising:
a) adding factor Xa inhibitor and excipients under continuous mixing using stirring, b) making the final volume with water for injection, and c) heating the mixture if required.
Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture if required.
Another embodiment of the present invention provides a process for preparing a non-oral formulation of factor Xa inhibitor comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents, stabilizers and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture if required.
DETAILED DESCRIPTION OF THE INVENTION
The term "comprising", which is synonymous with "including", "containing", or "characterized by" here is defined as being inclusive or open-ended, and does not exclude additional, unrecited elements or method steps, unless the context clearly requires otherwise.
The solubility of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban in this vehicle is atleast 1.5 mg/mL. The present invention has better acceptability as compared to earlier claimed inventions of the same group of drugs.
In an embodiment of present invention, the formulation is suitable for bolus injection, intravenous infusion, topical, nasal, transdermal and ophthalmic administration.
In another embodiment of the present invention is a method for treating the risk of stroke and systemic embolism in nonvalular atrial fibrillation patients and deep vein thrombosis and pulmonary embolism after hip or knee replacement surgery, administered to patient in need, thereof a non-oral formulation of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban are therapeutically active.
The subject invention describes new formulations of factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban for administration which includes non-oral formulation and method for making and using the same.
Drug solubility is minimum requirement for designing any dosage form and it is more critical when designing a formulation of poorly soluble drug like factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban. Because of low solubility associated with factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, the bioavailability is limited and hence, solubility enhancement is necessary.
The method of making and using novel non-oral formulation of poorly soluble factor Xa inhibitor such as Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban disclosed in this invention addresses the enhancement of patient acceptability for same class of drugs.
In accordance with current invention, it was observed that water solubility of factor Xa inhibitor was sufficiently increased to allow preparation of aqueous based non-oral formulation by using factor Xa inhibitor with surface active agents and cosolvents and solvent and solubilising agents and stabilizers.
Many different category of water miscible co-solvent system and solubilizing agents have proved to be unacceptable for liquid formulation of factor Xa inhibitor due to the limited solubility of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and
Betrixaban sufficiently to provide a drug concentration of at least 1.5 mg/mL at acceptable administrable volume.
The factor Xa inhibitor is selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
The factor Xa inhibitor used in formulations of present invention is in the range of about 0.001% to 10% w/w of total weight of the formulation.
The vehicle used in the formulations of the present invention is water.
The vehicle used in formulations of present invention is in the range of about 5% to 90% w/w of total weight of the formulation.
The surface active agents used in the present invention are selected from nonionic surface active agents such as polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), polyoxyethylene castor oil derivative, polyoxyglyceride, vitamin E polyethylene glycol succinate, and macrogol 15 hydroxystearate and combinations thereof.
The surface active agents used in formulations of present invention is in the range of about 0.001% to 40% w/w of total weight of the formulation.
The co- solvents used in the present invention are selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, ester of a medium or long chain fatty acid such as a mono- di- or triglyceride, phospholipids, dimethylsulfoxide, dimethylacetamide and combinations thereof.
The co- solvents used in formulations of present invention is in the range of about 1% to 90% w/w of total weight of the formulation.
The stabilizers used in the present invention are selected from glycerin, sorbitol, and mannitol.
The stabilizers used in formulations of present invention are in the range of
about 1% to 90% w/w of total weight of the formulation.
The said invention is stable as confirmed from stability studies conducted on prepared formulations.
The product thus formulated can be used for treatment of risk of stroke, systemic embolism in patients with nonvalvular atrial fibrillation, deep vein thrombosis and pulmonary embolism after hip or knee replacement surgery. As with any potent drug, the dosage must be individualized by treating clinician.
The formulation of the present invention is manufactured by dissolving surface active agent in vehicle followed by adding one or more co-solvent’s or co-solvent and stabilizer and finally adding factor Xa inhibitor in the vehicle under continuous mixing using stirring. Final volume was made up by water for injection. Mixture was heated at 40-80°C for 10-30 minutes if required, to obtain clear solution upon cooling to room temperature.
The solution was free from particulate matter by visual inspection and was filtered by sterilizing grade filter followed by aseptic filling into vials or ampoules or prefilled syringes. If required, the final product was sterilized by autoclaving. Target fill volume was 3.5 mL including 0.5 mL overfill for vial or needle or ampoule hold up.
The following examples describe the nature of the invention and are given only for the purpose of illustrating the present invention in more detail and are not limitative.
EXAMPLE 1
Manufacturing process
Dissolving Polysorbate 80 in water followed by adding Propylene glycol, Alcohol and finally adding Apixaban in the vehicle. Each component was added under continuous mixing using stirring. Final volume was made up by water for injection. Mixture was heated at 55-60°C for 10-30 minutes if required, to obtain clear solution upon cooling to room temperature. The solution was free from particulate matter by visual inspection and was filtered by sterilizing grade filter followed by aseptic filling into vials or ampoules or prefilled syringes. If required, the final product was sterilized by autoclaving. Target fill volume was 3.5 mL including 0.5 mL overfill for vial or needle or ampoules hold up.
The formulations of example 2 were prepared as per manufacturing process described in Example 1.
The formulations of example 3 were prepared as per manufacturing process described in Example 1. EXAMPLE 4
The formulations of example 4 were prepared as per manufacturing process described in Example 1.
EXAMPLE 5
The formulations of example 5 were prepared as per manufacturing process described in Example 1.
EXAMPLE 6
The formulations of example 6 were prepared as per manufacturing process described in Example 1.
The formulations of example 7 were prepared as per manufacturing process described in Example 1.
The formulations of example 8 were prepared as per manufacturing process described in Example 1.
EXAMPLE 9
The formulations of example 9 were prepared as per manufacturing process described in Example 1.
EXAMPLE 10
The formulations of example 10 were prepared as per manufacturing process described in Example 1.
EXAMPLE 11
Table No. 11: Composition for formulation 11
The formulations of example 11 were prepared as per manufacturing process described in Example 1.
The formulations of example 12 were prepared as per manufacturing process described in Example 1.
EXAMPLE 13
The formulations of example 13 were prepared as per manufacturing process described in Example 1.
EXAMPLE 14
The formulations of example 14 were prepared as per manufacturing process described in Example 1.
EXAMPLE 15
The formulations of example 15 were prepared as per manufacturing process described in Example 1.
EXAMPLE 16
Table No. 16: Composition for formulation 16
The formulations of example 16 were prepared as per manufacturing process described in Example 1.
The formulations of example 17 were prepared as per manufacturing process described in Example 1.
EXAMPLE 18
The formulations of example 18 were prepared as per manufacturing process described in Example 1.
EXAMPLE 19
The formulations of example 19 were prepared as per manufacturing process described in Example 1.
EXAMPLE 20
The formulations of example 20 were prepared as per manufacturing process described in Example 1.
While the invention has been described with reference to a particular embodiment, it will be understood by those expert in the skill that various alterations may be made
without deviating from the scope of invention. In addition to this, several alterations may be made to acclimatize a particular invention without deviating from the major scope. It is believed that the invention must not be restricted to particular embodiment disclosed as the best mode anticipated for carrying out of this invention, but then the invention will include all.
Claims
1. A novel non-oral formulation of factor Xa inhibitors comprising factor Xa inhibitor and pharmaceutically acceptable excipients selected from vehicles, surface active agents, co-solvents and stabilizers.
2. The formulation as claimed in claim 1, wherein factor Xa inhibitor is selected from the group of Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban.
3. The formulation as claimed in claim 1, wherein the said factor Xa inhibitor has solubility from 1.5 to about 2 mg/mL.
4. The formulation as claimed in claim 1, wherein vehicle is water.
5. The formulation as claimed in claim 1, wherein non-ionic surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), polyoxyethylene castor oil derivative, polyoxyglyceride, vitamin E polyethylene glycol succinate, and macrogol 15 hydroxystearate and combinations thereof.
6. The formulation as claimed in claim 1, wherein co- solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, ester of a medium or long chain fatty acid such as a mono- di- or triglyceride, phospholipids, dimethylsulfoxide, dimethylacetamide and combinations thereof.
7. The formulation as claimed in claim 1, wherein stabilizers are selected from glycerin, sorbitol, and mannitol.
8. The formulation as claimed in claims 1-8, wherein non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 5% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban,
b) 5% to 90% w/w of water as vehicle, c) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), and d) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof.
9. The formulation as claimed in claims 1-8, wherein non-oral formulation of factor Xa inhibitors comprising: a) 0.001% to 5% w/w of factor Xa inhibitor selected from Apixaban, Razaxaban, Edoxaban, Rivaroxaban and Betrixaban, b) 5% to 90% w/w of water as vehicle, c) 0.001% to 40% w/w of surface active agents selected from polyoxyethylene sorbitan fatty acid esters (Polysorbates), block copolymers of polyethylene glycol and propylene glycol (poloxamers), d) 10% to 90% w/w of co-solvents selected from alcohol, propylene glycol, ethyl alcohol, polyethylene glycol, glycerin, benzyl alcohol, dimethylsulfoxide, dimethylacetamide and combinations thereof and e) 1% to 30% w/w of stabilizers selected from glycerin, sorbitol, and mannitol.
10. The process for the preparation of formulation as claimed in claim 1, wherein said a process comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture.
11. The process for the preparation of formulation as claimed in claim 1, wherein said a process comprising: a) dissolving the surface active agent in vehicle, b) adding one or more co-solvents, stabilizers and factor Xa inhibitor in the vehicle under continuous mixing using stirring, c) making the final volume with water for injection, and d) heating the mixture.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202241063008 | 2022-11-04 | ||
IN202241063008 | 2022-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024095053A1 true WO2024095053A1 (en) | 2024-05-10 |
Family
ID=90929850
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/062795 WO2024095053A1 (en) | 2022-11-04 | 2022-12-27 | Novel non-oral formulations of factor xa inhibitors and process for preparation thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024095053A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210299059A1 (en) * | 2018-08-14 | 2021-09-30 | Jiangsu Hengrui Medicine Co., Ltd. | Injectable pharmaceutical composition and preparation method therefor |
WO2022056326A1 (en) * | 2020-09-11 | 2022-03-17 | Elixir Medical Corporation | Anticoagulant compounds, methods and devices for ophthalmic use |
BR102021018969A2 (en) * | 2020-09-25 | 2022-06-07 | Universidade Federal Do Rio De Janeiro | Rivaroxaban microemulsion-gel and rivaroxaban microemulsion-gel manufacturing process |
-
2022
- 2022-12-27 WO PCT/IB2022/062795 patent/WO2024095053A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210299059A1 (en) * | 2018-08-14 | 2021-09-30 | Jiangsu Hengrui Medicine Co., Ltd. | Injectable pharmaceutical composition and preparation method therefor |
WO2022056326A1 (en) * | 2020-09-11 | 2022-03-17 | Elixir Medical Corporation | Anticoagulant compounds, methods and devices for ophthalmic use |
BR102021018969A2 (en) * | 2020-09-25 | 2022-06-07 | Universidade Federal Do Rio De Janeiro | Rivaroxaban microemulsion-gel and rivaroxaban microemulsion-gel manufacturing process |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2429837C2 (en) | Pharmaceutical composition of taxan, solid composition of taxan, method of producing solid composition of taxan, composition for solubilisation of said solid composition of taxan and set of elements (kit) for composition of taxan for injections | |
JP5668004B2 (en) | Aqueous pharmaceutical composition of 2,6-diisopropylphenol (propofol) and use thereof | |
RU2345772C2 (en) | Lyophilised compositions cci-779 | |
JP6356873B2 (en) | Taxane active ingredient-containing liquid composition and liquid formulation | |
EA035079B1 (en) | Diclofenac composition | |
JP6818019B2 (en) | Injectable pharmaceutical composition of lefamulin | |
US8153696B2 (en) | Medicinal preparation particularly for the treatment of slipped discs hernias | |
EA016619B1 (en) | Novel taxoid-based compositions | |
JP2007515425A (en) | Pharmaceutical composition | |
JPH06219948A (en) | Antithrombin agent and its production | |
TW202245791A (en) | Pharmaceutical formulation | |
WO2024095053A1 (en) | Novel non-oral formulations of factor xa inhibitors and process for preparation thereof | |
JP2011529930A (en) | Injectable taxane pharmaceutical composition | |
RU2370261C2 (en) | Stable emulsion for parenteral introduction of badly soluble in water compounds, which have anti-tumor activity, and method of its obtaining | |
KR20150112975A (en) | Stable pharmaceutical composition of clopidogrel free base for oral and parenteral delivery | |
JP2018530597A (en) | Fulvestrant composition | |
RU2236227C1 (en) | Stable pharmaceutical formulation of anticancer preparation | |
KR20210102936A (en) | Stable anesthetic formulations and related dosage forms | |
CN113797167B (en) | Reservoir preparation of celebrarphine | |
JP2015520142A (en) | Parenteral esmolol preparation | |
US7645765B2 (en) | Use of moxaverin for treating erectile dysfunction, forms of dementia or diseases associated to an arteriosclerotic occlusion | |
WO2024075135A1 (en) | "stable injectable compositions of glp-2 peptide" | |
Strickley | Solubilizing excipients in pharmaceutical formulations | |
WO2024062504A1 (en) | Pharmaceutical composition comprising ubrogepant and administration thereof | |
WO2011101865A2 (en) | Stable pharmaceutical compositions of clopidogrel for parenteral delivery |